Allogene Therapeutics Announces Participation in December Investor Conferences

Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on allogeneic CAR T products for cancer and autoimmune disease, has announced its participation in upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference on November 20, 2024, at 11:30AM GMT, the Citizens JMP Hematology and Oncology Summit on December 2, 2024, and the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024. Webcasts will be available on the company's website for approximately 30 days after the events.

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed.

TIME UPDATE: Jefferies London Healthcare Conference
Wednesday, November 20, 2024
11:30AM GMT/ 6:30AM ET

The Citizens JMP Hematology and Oncology Summit (Virtual)
Monday, December 2, 2024
8:00AM PT/11:00AM ET

36th Annual Piper Sandler Healthcare Conference
Tuesday, December 3, 2024
5:00AM PT/8:00AM ET

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

When is Allogene Therapeutics (ALLO) presenting at the Jefferies London Healthcare Conference 2024?

Allogene Therapeutics will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 11:30AM GMT/6:30AM ET.

Which investor conferences will Allogene Therapeutics (ALLO) attend in December 2024?

Allogene Therapeutics will attend the Citizens JMP Hematology and Oncology Summit on December 2, 2024, and the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024.

How long will Allogene Therapeutics (ALLO) conference webcasts be available for viewing?

Webcasts of the conferences will be available on Allogene's website for approximately 30 days following the live events.